Abstract
Systemic light chain amyloidosis (AL) is a kind of plasma disease which leads to tissue and organ dysfunction caused by the deposit of monoclonal immunoglobulin light chain. Autologous peripheral blood stem cell transplantation (APBSCT) is the first-line treatment for patients with confirmed AL. For the ones unengaging the transplantation, chemotherapy can improve the response rate and prolong the survival. Current ways of chemotherapy include proteasome inhibitors, immunomodulatory agents and alkylating agents. In recent years, immunotherapy represented by NEOD001 and antibodies to serum amyloid P component (SAP) has showed to be significantly effective. The clinical response of clarithromycin, doxycycline and epigallocatechin gallate (EGCG) is still under exploration. The article reviews the advance in treatment of AL. Key words: Amyloidosis; Peripheral blood stem cell transplantation; Immunotherapy; Chemotherapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
